Draft. Pending scientific and legal review. Not medical advice.

Clinical genetics: single-gene tests

Single-gene clinical genetics studies specific genes linked to known conditions. Methods may include Sanger sequencing, targeted NGS, genotyping or triplet-repeat expansion analysis. Indication, consent and genetic counselling, where required, are set by the healthcare professional.

What this area studies

Single-gene tests target individual genes with evidence of association to specific diseases or clinical traits. The Xenomium catalogue includes, among others, studies of APOE, APP, BRCA1, BRCA2, NOTCH3 (CADASIL), HTT (Huntington), PSEN1, PSEN2, SNCA, SOD1 and expansions linked to spinocerebellar ataxias (ATXN1, ATXN2, ATXN3) or Friedreich ataxia (FXN).

Scope differs from a broad NGS panel or a susceptibility profile: here the study targets one gene or a tightly defined pair, with the method suited to the variant sought.

Common methods

Depending on the gene and variant type, the method may be:

- Sanger sequencing of a single gene. - NGS of a small set (for example BRCA1 and BRCA2). - Genotyping of known alleles (for example APOE E2/E3/E4). - Triplet-repeat expansion analysis with screening and, where appropriate, TP-PCR.

Each catalogue sheet states the method. Variant interpretation draws on frameworks such as ACMG/AMP recommendations and evidence-curation resources such as ClinGen, when they apply to the gene or variant.

When a single-gene test makes sense

A single-gene study is often indicated when clinical suspicion points to a specific gene or mechanism (for example a triplet-repeat expansion, a cardiomyopathy gene or a tightly defined cancer-predisposition gene). If the phenotype is broad or non-specific, the professional may consider an NGS panel, an exome or a genome, described in the sequencing area.

GeneReviews and Orphanet help situate evidence on genes and syndromes. They do not replace family history or clinical examination. ESHG publishes ethical and professional frameworks on genetic testing in Europe that guide good practice without setting the indication for an individual case.

High-consequence tests

Some tests are high-consequence and presymptomatic. Huntington, PSEN1, PSEN2, APP, SOD1, ataxias and CADASIL are not requested through the site form. They require a documented clinical indication and prior genetic counselling. The medical lead sets the protocol before they are offered.

A genetic result may affect biological relatives. It may include unsolicited findings. This page does not replace pre-test information or consent.

What remains pending

Pending Phase 0: usual sample, turnaround, coverage or sensitivity per test, and confirmation of anomalous gene identifiers in lists. Until those data exist, this page describes study types and cautions, not analytical performance claims.

Sources

Request through your healthcare professional